— Branded Pharmaceuticals revenues decreased by 2% due to the ongoing generic competition in the Established Products portfolio.
— Specialty Products revenues increased by 15% primarily driven by the continued strong performance of Xiaflex. The demand growth in both the Peyronie’s Disease and Dupuytren’s Contracture indications drove Xiaflex sales higher.
— Revenues of the Sterile Injectables segment increased by 10% to $285 million. This was driven by the continued strong growth of Vasostrict and Adrenalin.
— Generic Pharmaceuticals revenues dropped by 14% due to the continued competitive pressure on commoditized generic products. The ongoing generic competition also hurt the International Pharmaceuticals revenue, which fell by 16%.
— Looking ahead into the full year 2020, the company expects total revenue of $2.72-2.92 billion and adjusted EPS from continuing operations of $2.15-2.40. The consensus estimates EPS of $2.25 on revenue of $2.90 billion.